Andy Ko is a Senior Research Associate at Quell Therapeutics, specializing in the Analytical Development team with a focus on developing, optimizing, and evaluating molecular assays using qPCR and dPCR since July 2023. Prior experience includes serving as a Technology Analyst at IDTechEx, where insights were gathered on emerging technologies in life sciences, as well as engaging in multiple research projects at Imperial College London, investigating topics such as blast traumatic brain injury and the immune response to SARS-CoV-2. Early career experience includes roles at The Francis Crick Institute and Imperial College London, where contributions were made to projects on CNS metabolism and malaria gene drive strategies. Andy holds a Master’s of Research in Cell/Cellular and Molecular Biology and a Bachelor of Science in Biology/Biological Sciences, both from Imperial College London.
This person is not in any teams